Department of Medicine, Yale University School of Medicine, Yale University, New Haven, Department of Medicine, VA Connecticut Health Care System, West Haven, CT, Department of Psychology, Yeshiva University, New York, NY and Department of Research, VA Central Western Massachusetts, North Hampton, MA, USA. Department of Medicine, Yale University School of Medicine, Yale University, New Haven, Department of Medicine, VA Connecticut Health Care System, West Haven, CT, Department of Psychology, Yeshiva University, New York, NY and Department of Research, VA Central Western Massachusetts, North Hampton, MA, USA.
Department of Medicine, Yale University School of Medicine, Yale University, New Haven, Department of Medicine, VA Connecticut Health Care System, West Haven, CT, Department of Psychology, Yeshiva University, New York, NY and Department of Research, VA Central Western Massachusetts, North Hampton, MA, USA.
Rheumatology (Oxford). 2015 Feb;54(2):278-85. doi: 10.1093/rheumatology/keu324. Epub 2014 Aug 28.
We performed a qualitative study to better understand how patients with RA approach risk-benefit trade-offs inherent in the choice of remaining with their current treatment vs escalating care.
We used a think-aloud protocol to examine how patients with RA approach risk-benefit trade-offs inherent in the choice of remaining with their current treatment vs adding a biologic. The data emerging from the protocols were used to develop a conceptual model describing how patients approach the decision to escalate care.
Participants who were strongly impacted by their disease were not open to considering alternative options. For some patients, being highly impacted by their disease results in a strong preference to escalate care. For others, the same level of distress is reason to unconditionally refuse additional medications. In contrast, those who were moderately impacted were more open to consider treatment options. Among these participants, however, subjects' risk-benefit trade-offs were consistently modified by factors unrelated to medication, including sociodemographic characteristics, role responsibilities and the quality of the patient-physician relationship.
The conceptual model indicates that patients approach the decision to escalate care differently from physicians. In order to improve care in RA, it is important to recognize that many patients with moderate to high disease activity are not open to alternative treatments, which is a prerequisite to engaging in decision making. Routine clinical encounters should enable health care providers to identify these patients in order to tailor education prior to recommending treatment escalation.
我们进行了一项定性研究,以更好地了解类风湿关节炎(RA)患者如何权衡其目前治疗方案与升级治疗方案之间固有的风险与获益。
我们采用出声思维法来研究 RA 患者在权衡继续现有治疗方案与增加生物制剂治疗之间的固有风险与获益时的决策过程。通过对思维过程的分析,我们开发了一个描述患者如何做出升级治疗决策的概念模型。
受疾病严重影响的患者不倾向于考虑替代方案。对于一些患者,疾病对其产生了严重影响,导致他们强烈倾向于升级治疗。而对于另一些患者,同样程度的痛苦则使他们无条件地拒绝使用其他药物。相比之下,那些受疾病中度影响的患者更愿意考虑治疗选择。然而,在这些患者中,药物以外的因素(包括社会人口学特征、角色责任和医患关系质量)不断改变他们的风险与获益权衡。
该概念模型表明,患者在决定升级治疗方案时与医生的观点存在差异。为了改善 RA 的治疗,重要的是要认识到许多中重度疾病活动度的患者对替代治疗不感兴趣,这是进行决策的前提。常规的临床接触应使医疗保健提供者能够识别这些患者,以便在推荐治疗升级之前进行个性化的教育。